PCI Biotech Holding ASA (PCIB.OL)
NOK 1.34
(0.38%)
NOK 1.34
(0.38%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.54 NOK | 62.5% |
| 2022 | -1.44 NOK | 39.24% |
| 2021 | -2.37 NOK | -21.54% |
| 2020 | -1.95 NOK | 18.75% |
| 2019 | -2.40 NOK | -92.0% |
| 2018 | -1.25 NOK | 28.98% |
| 2017 | -1.76 NOK | 12.44% |
| 2016 | -2.01 NOK | 5.19% |
| 2015 | -2.12 NOK | 34.16% |
| 2014 | -3.22 NOK | -50.47% |
| 2013 | -2.14 NOK | -8.63% |
| 2012 | -1.97 NOK | -84.11% |
| 2011 | -1.07 NOK | 15.08% |
| 2010 | -1.26 NOK | 23.64% |
| 2009 | -1.65 NOK | -10.0% |
| 2008 | -1.50 NOK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.10 NOK | 9.82% |
| 2024 Q2 | -0.10 NOK | 0.0% |
| 2023 Q2 | -0.15 NOK | 0.0% |
| 2023 FY | - NOK | 62.5% |
| 2023 Q4 | -0.11 NOK | 0.0% |
| 2023 Q3 | -0.11 NOK | 26.67% |
| 2023 Q1 | -0.15 NOK | 11.76% |
| 2022 Q4 | -0.17 NOK | 39.29% |
| 2022 FY | - NOK | 39.24% |
| 2022 Q1 | -0.62 NOK | 22.5% |
| 2022 Q2 | -0.37 NOK | 40.32% |
| 2022 Q3 | -0.28 NOK | 24.32% |
| 2021 Q4 | -0.80 NOK | -40.35% |
| 2021 Q2 | -0.49 NOK | 23.44% |
| 2021 Q1 | -0.64 NOK | 9.86% |
| 2021 FY | - NOK | -21.54% |
| 2021 Q3 | -0.57 NOK | -16.33% |
| 2020 Q2 | -0.78 NOK | -750.0% |
| 2020 Q3 | -0.57 NOK | 26.92% |
| 2020 Q4 | -0.71 NOK | -24.56% |
| 2020 FY | - NOK | 18.75% |
| 2020 Q1 | 0.12 NOK | 117.65% |
| 2019 FY | - NOK | -92.0% |
| 2019 Q2 | -0.70 NOK | -14.75% |
| 2019 Q4 | -0.68 NOK | -78.95% |
| 2019 Q3 | -0.38 NOK | 45.71% |
| 2019 Q1 | -0.61 NOK | -369.23% |
| 2018 FY | - NOK | 28.98% |
| 2018 Q4 | -0.13 NOK | 60.61% |
| 2018 Q3 | -0.33 NOK | -13.79% |
| 2018 Q2 | -0.29 NOK | 50.0% |
| 2018 Q1 | -0.58 NOK | -34.88% |
| 2017 Q4 | -0.43 NOK | -4.88% |
| 2017 FY | - NOK | 12.44% |
| 2017 Q1 | -0.40 NOK | -122.22% |
| 2017 Q2 | -0.26 NOK | 35.0% |
| 2017 Q3 | -0.41 NOK | -57.69% |
| 2016 Q1 | -0.44 NOK | -4.76% |
| 2016 FY | - NOK | 5.19% |
| 2016 Q4 | -0.18 NOK | 68.97% |
| 2016 Q3 | -0.58 NOK | -1.75% |
| 2016 Q2 | -0.57 NOK | -29.55% |
| 2015 Q3 | -0.43 NOK | -38.71% |
| 2015 FY | - NOK | 34.16% |
| 2015 Q1 | -0.47 NOK | 40.51% |
| 2015 Q2 | -0.31 NOK | 34.04% |
| 2015 Q4 | -0.42 NOK | 2.33% |
| 2014 Q1 | -0.71 NOK | -2.9% |
| 2014 Q2 | -0.73 NOK | -2.82% |
| 2014 Q3 | -0.74 NOK | -1.37% |
| 2014 Q4 | -0.79 NOK | -6.76% |
| 2014 FY | - NOK | -50.47% |
| 2013 Q1 | -0.53 NOK | 18.46% |
| 2013 Q2 | -0.42 NOK | 20.75% |
| 2013 Q3 | -0.51 NOK | -21.43% |
| 2013 Q4 | -0.69 NOK | -35.29% |
| 2013 FY | - NOK | -8.63% |
| 2012 Q1 | -0.43 NOK | -38.71% |
| 2012 Q4 | -0.65 NOK | -10.17% |
| 2012 Q3 | -0.59 NOK | -103.45% |
| 2012 Q2 | -0.29 NOK | 32.56% |
| 2012 FY | - NOK | -84.11% |
| 2011 Q1 | -0.25 NOK | 32.43% |
| 2011 FY | - NOK | 15.08% |
| 2011 Q2 | -0.33 NOK | -32.0% |
| 2011 Q3 | -0.17 NOK | 48.48% |
| 2011 Q4 | -0.31 NOK | -82.35% |
| 2010 Q3 | 0.15 NOK | 122.73% |
| 2010 Q1 | -0.43 NOK | -22.86% |
| 2010 FY | - NOK | 23.64% |
| 2010 Q2 | -0.66 NOK | -53.49% |
| 2010 Q4 | -0.37 NOK | -346.67% |
| 2009 Q4 | -0.35 NOK | 5.41% |
| 2009 Q3 | -0.37 NOK | 7.5% |
| 2009 Q2 | -0.40 NOK | 0.0% |
| 2009 FY | - NOK | -10.0% |
| 2008 FY | - NOK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arctic Bioscience AS | -1.79 NOK | 69.832% |
| Aqua Bio Technology ASA | -0.99 NOK | 45.455% |
| ArcticZymes Technologies ASA | 0.38 NOK | 242.105% |
| BerGenBio ASA | -13.30 NOK | 95.94% |
| Hofseth BioCare ASA | -0.27 NOK | -100.0% |
| Thor Medical ASA | -0.03 NOK | -1598.113% |
| Ultimovacs ASA | -5.50 NOK | 90.182% |